SASHA LATYPOVA: Explains how "PfizerForAll" has been rebranded as "TrumpRx" and how Trump could make $500 million/year off the deal . . .

Pharma insider Sasha Latypova explains how "PfizerForAll" has been rebranded as "TrumpRx" and how Trump could make $500 million/year off the deal:

"[Pfizer's] being forced to license Trump's name...based on previous deals...typical terms are...3-5% off wholesale revenue."

For… pic.twitter.com/8fn2kCfvYJ

— Sense Receptor (@SenseReceptor) October 1, 2025

Pharma insider Sasha Latypova explains how "PfizerForAll" has been rebranded as "TrumpRx" and how Trump could make $500 million/year off the deal: "[Pfizer's] being forced to license Trump's name...based on previous deals...typical terms are...3-5% off wholesale revenue." For reference, Latypova notes that PfizerForAll, which appeared in the news in 2024, was/is a direct-to-consumer online retail pharmacy "with the capability of searching drugs and ordering and getting discounts directly from Pfizer." Per White House Press Secretary Karoline Leavitt, TrumpRx "is...a direct-to-consumer website for Americans to buy drugs." Note that Latypova says that while the Trump administration has advertised this site as a way for Medicaid patients to save money, this is not truthful, as "Medicaid patients don't pay for their drugs." This clip of Latypova (

@sasha_latypova

) is taken from an interview with Shannon Joy (

@ShannonJoyRadio

) posted to Rumble on October 1, 2025.